Skip to content

A clinical trial of balloon dilatation catheters

Prospective, multicenter, single-group clinical trial of efficacy and safety of balloon dilatation catheters for transcatheter aortic valve replacement

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000032202
Enrollment
Unknown
Registered
2020-04-23
Start date
2019-05-01
Completion date
Unknown
Last updated
2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with aortic stenosis planning to undergo transcatheter artificial aortic valve replacement

Interventions

Case series:Before performing transcatheter artificial aortic valve replacement, the subjects used a special balloon expansion catheter to pre-expand the valve release area to optimize the aortic valv

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with severe aortic valve stenosis are not suitable for surgical aortic valve replacement when undergoing transcatheter artificial aortic valve replacement; 2. Meet the requirements for receiving transcatheter artificial aortic valve replacement; 3. Meet the requirements of pre-dilatation balloon for transcatheter artificial aortic valve replacement; 4. Expected survival at least until the end of follow-up; 5. Agree to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Have undergone any form of aortic valve surgery; 2. Preoperative echocardiographic examination showed >=3 grade aortic insufficiency, or transesophageal ultrasound (TEE) before balloon predilation showed >=3 grade aortic insufficiency; 3. Non-valvular aortic stenosis; 4. Known congenital aortic valve abnormalities, but does not include bivalved aortic valve; 5. Cardiogenic shock, defined as systolic blood pressure continuously below 80 mmHg (without booster medication) or below 90 mmHg (with booster medication); 6. History of bacterial endocarditis within 12 months before surgery; 7. Can't take aspirin or thienopyridine; 8. Echocardiography revealed intracardiac masses, thrombi or neoplasms; 9. Any situation judged by the investigator that affects the safety or treatment outcome of the subject.

Design outcomes

Primary

MeasureTime frame
Success rate of balloon expansion catheter fixation;

Secondary

MeasureTime frame
Immediate surgical success rate;Rapid cardiac pacing (RVP) rate, pacing frequency and time during balloon dilatation catheter release;All-cause mortality;Incidence of nonfatal stroke;Emergency or unplanned cardiac surgery or cardiac intervention related to the use of the balloon dilatation catheter;Severe aortic valve insufficiency (4+), or increased aortic valve insufficiency grade by 2 or more;Severe vascular complications (VARC II definition);Myocardial infarction (VARC II defined standard);Angiography confirmed rupture of the annulus or aortic root caused by the expansion of the test balloon dilatation catheter;Other adverse events related to test device;Test balloon dilatation catheter size, number of attempts to release balloon dilatation catheter, and number of uses;Test balloon inflation catheter filling pressure, filling volume, test balloon inflation catheter rupture ratio;Test balloon dilatation catheter usage time (minutes), the time from the test balloon dilatation catheter entering the arterial access sheath to the withdrawal of all sheaths;

Countries

China

Contacts

Public ContactChen Mao

West China Hospital, Sichuan University

hmaochen@vip.sina.com+86 18908062046

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026